Understanding RSV: A Danger to Our Most Vulnerable Populations
Great news for the prevention of respiratory syncytial virus (“RSV”) infections! Here’s a quick summary of the article:
- RSV is a significant global health challenge, causing thousands of hospitalizations and deaths annually in the US and many more worldwide, particularly among infants and older adults.
- Calder Biosciences has developed a groundbreaking technology, 3D-VAXLOCK™, which boosts immune activity significantly more than current standards and offers improved vaccine shelf-life.
- Crowley Law is proud to support Calder Biosciences as legal counsel, demonstrating the potential for legal expertise to facilitate advancements in life sciences.
The Unseen Threat: RSV’s Impact on Vulnerable Groups
RSV is a common respiratory virus that causes mild, cold-like symptoms in most children and adults. However, that’s not the case for infants and adults aged 65 and older.
Global Impact and Mortality
The disease causes approximately 58,000 hospitalizations in the United States among children under five years old. RSV infection is estimated to cause about 14,000 deaths annually in the United States in adults over age 65 years of age. Globally, RSV affects an estimated 64 million people and causes approximately 160,000 deaths each year.
Why Are Infants and Seniors Most Susceptible to Severe RSV?
In the case of infants, their immune systems have not developed to the point where they can competently fight off the infection. This can result in lifelong damage to their lungs. In older adults, their immune systems become less active and consequently less able to fight off infections. This can be particularly problematic for older adults with other chronic medical conditions. So, RSV infections in this population can have very serious consequences and require hospitalization.
3D-VAXLOCK™: A Breakthrough in the Fight Against RSV
Our client, Calder Biosciences, has developed a technology that can make great strides in taming this malady. Calder’s innovation, 3D-VAXLOCK™ technology, has resulted in immune activity that is more than ten times greater than the industry standard comparator. The technology also improves the shelf-life of the vaccine at refrigerated temperatures and will facilitate the distribution and delivery of the vaccine.
Research Insights: Calder Biosciences Featured in “Nature Communications”
The development is described in detail in Calder’s recent paper in Nature Communications.
Crowley Law: Supporting Innovation in Life Sciences
Crowley Law is delighted to be legal counsel to such an innovative company. If you have an innovation in the life sciences or other technology areas and need help in moving it forward, contact us at (908) 540-6901 or [email protected] to schedule a complimentary call with a member of our team. We’re here to help.
RSV-Hospitalizations-and-Deaths-Reduced-by-Innovative-3D-VAXLOCK-Vaccine-Technology